Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

Company Overview

Unicycive Therapeutics is a clinical‐stage biopharmaceutical company focused on developing next‐generation immunomodulatory therapies for autoimmune and inflammatory diseases. Founded in 2015 as a spin‐out from academic research at the Massachusetts Institute of Technology, the company leverages its proprietary Cycive peptide platform to engineer cyclic peptides with enhanced stability, selectivity and tissue penetration. By harnessing this platform, Unicycive aims to address unmet medical needs in conditions such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

The company’s lead programs include UCV‐101, a cyclic peptide inhibitor of the IL‐17 receptor currently in Phase 2 clinical trials for moderate to severe rheumatoid arthritis, and UCV‐201, a tissue‐targeted peptide designed to modulate intestinal inflammation in Crohn’s disease. Unicycive has also initiated early‐stage studies of UCV‐301, an experimental therapy targeting neuroinflammation in relapsing‐remitting multiple sclerosis. In addition to its in‐house pipeline, Unicycive maintains strategic collaborations with several pharmaceutical partners to co‐develop and commercialize select assets in global markets.

Headquartered in Cambridge, Massachusetts, Unicycive Therapeutics maintains research facilities in Boston and a clinical development office in London to manage its expanding European trial footprint. Under the leadership of CEO Dr. Evelyn Chang, a veteran of immunology drug development, the company is supported by a seasoned management team including Chief Scientific Officer Dr. Ravi Kumar and Chief Business Officer Mark Johnson. With an experienced board of directors and advisory committees comprised of leading immunologists and clinicians, Unicycive continues to drive its programs toward regulatory milestones and potential commercialization.

Key Stats

• Today's Range: $4.62 to $5.08
• 50-Day Range: $4.64 to $9.00
• 52-Week Range: $2.02 to $11.00
• Volume: 637,594 shs
• Average Volume: 269,311 shs
• Market Capitalization: $62.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Strong Buy

Unicycive Therapeutics Stock Analysis - MarketRank™

Unicycive Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 362nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Unicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Unicycive Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.23) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Unicycive Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Unicycive Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Unicycive Therapeutics has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.49% of the float of Unicycive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Unicycive Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Unicycive Therapeutics has recently increased by 3.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Unicycive Therapeutics does not currently pay a dividend.

Dividend Growth

Unicycive Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.49% of the float of Unicycive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Unicycive Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Unicycive Therapeutics has recently increased by 3.47%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.38

News Sentiment

Unicycive Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Unicycive Therapeutics this week, compared to 2 articles on an average week.

Search Interest

38 people have searched for UNCY on MarketBeat in the last 30 days. This is an increase of 192% compared to the previous 30 days.

MarketBeat Follows

9 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.71% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

UNCY Stock Analysis - Frequently Asked Questions

How have UNCY shares performed this year?

Unicycive Therapeutics' stock was trading at $7.9420 on January 1st, 2025. Since then, UNCY shares have decreased by 37.4% and is now trading at $4.97.

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.40) by $0.90.

When did Unicycive Therapeutics' stock split?

Shares of Unicycive Therapeutics reverse split on Friday, June 20th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Unicycive Therapeutics IPO?

Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering (IPO) on Tuesday, July 13th 2021. The company issued 4,600,000 shares at a price of $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Unicycive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UNCY
• CIK: 1766140
• Web: www.unicycive.com
• Phone: 650-351-4495
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Unicycive Therapeutics: $60.00
• High Price Target: $90.00
• Low Price Target: $30.00
• Potential Upside/Downside: +1,107.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -277.30%
• Return on Assets: -61.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.64
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $680 thousand
• Price / Sales: 92.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 6.90

Miscellaneous

• Outstanding Shares: 12,640,000
• Free Float: 11,287,000
• Market Cap: $62.82 million
• Optionable: Not Optionable
• Beta: 1.89